Generalized Anxiety Disorder Adjunct Study
Study identifier:D1441L00016
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Rand., Double-blind, Parallel-group, Pbo-controlled Study of the Efficacy and Safety of SEROQUEL® XR Compared with Pbo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination with a Benzo
Medical condition
Anxiety
Phase
Phase 3
Healthy volunteers
No
Study drug
Placebo, quetiapine fumarate XR
Sex
All
Actual Enrollment
409
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Aug 2007
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: 1 Adjunctive Placebo Seroquel XR to anxiety treatment | Drug: Placebo oral |
| Experimental: 2 Adjunctive Seroquel XR to anxiety treatment | Drug: quetiapine fumarate XR oral Other Name: Seroquel XR |
Contacts
Investigators
Principal Investigator
Martin Brecher
AstraZeneca
